Five Myths About DCTs: Why Small And Midsized Biotechs Have An Advantage

One fact is clear: decentralized clinical trials (DCTs) are here to stay. While this is excellent news for patients, sponsors now face the complexities of revamping trial design, protocols, staffing, and technology—in short, their whole approach to trial execution. This may seem like a daunting challenge for resource-constrained small and mid-sized biotech companies. Yet, in truth, their relative nimbleness can be a tremendous advantage. Here, we explore five myths about DCTs and explain why the truth often benefits the smaller player.